DZ2003A1 - Dérivés de la benzazépine, de la benzoxazépine et de l'acide benzothiazépine-n-acétique ainsi que leurs procédés de preparation et médicaments contenant ces composés. - Google Patents

Dérivés de la benzazépine, de la benzoxazépine et de l'acide benzothiazépine-n-acétique ainsi que leurs procédés de preparation et médicaments contenant ces composés.

Info

Publication number
DZ2003A1
DZ2003A1 DZ960044A DZ960044A DZ2003A1 DZ 2003 A1 DZ2003 A1 DZ 2003A1 DZ 960044 A DZ960044 A DZ 960044A DZ 960044 A DZ960044 A DZ 960044A DZ 2003 A1 DZ2003 A1 DZ 2003A1
Authority
DZ
Algeria
Prior art keywords
benzoxazepine
benzothiazepine
benzazepine
compounds
well
Prior art date
Application number
DZ960044A
Other languages
English (en)
Inventor
Harald Waldeck
Dagmar Holtje
Josef Messinger
Original Assignee
Kali Chemie Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kali Chemie Pharma Gmbh filed Critical Kali Chemie Pharma Gmbh
Application granted granted Critical
Publication of DZ2003A1 publication Critical patent/DZ2003A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ960044A 1995-03-23 1996-03-17 Dérivés de la benzazépine, de la benzoxazépine et de l'acide benzothiazépine-n-acétique ainsi que leurs procédés de preparation et médicaments contenant ces composés. DZ2003A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19510566A DE19510566A1 (de) 1995-03-23 1995-03-23 Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
DZ2003A1 true DZ2003A1 (fr) 2002-07-20

Family

ID=7757471

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ960044A DZ2003A1 (fr) 1995-03-23 1996-03-17 Dérivés de la benzazépine, de la benzoxazépine et de l'acide benzothiazépine-n-acétique ainsi que leurs procédés de preparation et médicaments contenant ces composés.

Country Status (25)

Country Link
US (1) US5677297A (fr)
EP (1) EP0733642B1 (fr)
JP (1) JP3942670B2 (fr)
KR (1) KR100482499B1 (fr)
CN (1) CN1059436C (fr)
AR (1) AR023289A1 (fr)
AT (1) ATE197801T1 (fr)
AU (1) AU701271B2 (fr)
CA (1) CA2172354C (fr)
CZ (1) CZ289245B6 (fr)
DE (2) DE19510566A1 (fr)
DK (1) DK0733642T3 (fr)
DZ (1) DZ2003A1 (fr)
ES (1) ES2152444T3 (fr)
GR (1) GR3035410T3 (fr)
HU (1) HU226064B1 (fr)
IL (1) IL117265A (fr)
NO (1) NO305904B1 (fr)
NZ (1) NZ286224A (fr)
PL (1) PL184336B1 (fr)
PT (1) PT733642E (fr)
RU (1) RU2159768C2 (fr)
SK (1) SK281079B6 (fr)
UA (1) UA44712C2 (fr)
ZA (1) ZA961243B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2781483A1 (fr) * 1998-07-21 2000-01-28 Hoechst Marion Roussel Inc Derives de thioazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicament et compositions pharmaceutiques les renfermant
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
RU2003136077A (ru) * 2001-05-18 2005-08-10 Зольвай Фармасьютиклз Гмбх (De) Применение соединений, обладающих совместной ингибирующей активностью в отношении nep (нейтральная эндопептидаза) и мр (металлопротеаза), для приготовления лекарственных средств
ATE453648T1 (de) * 2001-09-10 2010-01-15 Tibotec Pharm Ltd Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
KR100710547B1 (ko) * 2002-01-02 2007-04-24 에스케이 주식회사 (s)-3-아미노-2,3,4,5-테트라히드로-2-옥소-1H-벤자제핀-1-아세트산 및 이의 에스테르 화합물의 제조방법
CN100591689C (zh) * 2002-01-16 2010-02-24 索尔瓦药物有限公司 苯并氮杂环庚三烯化合物的固体盐及其在制备药物化合物中的应用
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US6842358B2 (en) * 2002-08-01 2005-01-11 Netlogic Microsystems, Inc. Content addressable memory with cascaded array
US7045653B2 (en) * 2002-12-23 2006-05-16 Pfizer, Inc. Pharmaceuticals
KR100710548B1 (ko) * 2002-12-26 2007-04-24 에스케이 주식회사 (s)-3-아미노-2,3,4,5-테트라히드로-2-옥소-1H-1-벤자제핀-1-아세트산 및 이의 에스테르 화합물의 제조방법
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
DE10344848A1 (de) * 2003-09-26 2005-04-14 Solvay Pharmaceuticals Gmbh Amidomethyl-substituierte l-(Carboxyalkyl)-cyclopentylcarbonylamino-benzazepin-N-essigsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enhaltende Arzneimittel
PL1687006T3 (pl) * 2003-11-18 2008-01-31 Solvay Pharm Gmbh Kompozycje farmaceutyczne do leczenia zaburzeń czynności nerek
SI1706121T1 (sl) * 2004-01-12 2009-02-28 Solvay Pharm Bv Inhibitorji nevtralne endopeptidaze (nep) in humane topne endopeptidaze (hsep) za profilakso in zdravljenje nevrodegenerativnih motenj
US7232813B2 (en) * 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
CA2579716A1 (fr) * 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at<sb>1</sb>
JP2008524159A (ja) 2004-12-15 2008-07-10 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング NEP阻害剤、内因性エンドセリン産生系の阻害剤およびHMGCoAレダクターゼ阻害剤を含有する医薬組成物
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
WO2007102171A2 (fr) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Nouveaux sels de l'acide 1h-1-benzazépine-1-acétique, préparation de ceux-ci et composition pharmaceutique comprenant ceux-ci
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent
EP2543368A1 (fr) 2007-12-11 2013-01-09 Viamet Pharmaceuticals, Inc. Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
AR079059A1 (es) 2009-12-07 2011-12-21 Abbott Healthcare Products Bv Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
CN103189053A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 用于体重控制的5-ht2c激动剂的调节释放剂型
SG188365A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
US8993631B2 (en) * 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
MX2013006805A (es) 2010-12-15 2013-07-29 Theravance Inc Inhibidores de la neprilisina.
WO2012082857A1 (fr) 2010-12-15 2012-06-21 Theravance, Inc. Inhibiteurs de néprilysine
BR112013020996A8 (pt) 2011-02-17 2017-12-26 Theravance Inc derivados aminobutíricos substituídos como inibidores de neprilisina
ES2564275T3 (es) 2011-02-17 2016-03-21 Theravance Biopharma R&D Ip, Llc Derivados aminobutíricos sustituidos como inhibidores de neprilisina
EP2714662B1 (fr) 2011-05-31 2017-10-11 Theravance Biopharma R&D IP, LLC Inhibiteurs de neprilysine
EP2714660B1 (fr) 2011-05-31 2018-09-26 Theravance Biopharma R&D IP, LLC Inhibiteurs de néprilysine
US8686184B2 (en) 2011-05-31 2014-04-01 Theravance, Inc. Neprilysin inhibitors
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
WO2013181332A1 (fr) 2012-05-31 2013-12-05 Theravance, Inc. Inhibiteurs de néprilysine donneurs d'oxyde nitrique
BR112014030743B1 (pt) 2012-06-08 2022-09-06 Theravance Biopharma R&D Ip, Llc Composto inibidor de neprilisina, processo para a preparação do referido composto, composição farmacêutica e uso do referido composto
WO2013184898A1 (fr) 2012-06-08 2013-12-12 Theravance, Inc. Inhibiteurs de la néprilysine
RU2650114C2 (ru) 2012-08-08 2018-04-09 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Ингибиторы неприлизина
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規使用
EP2964616B1 (fr) 2013-03-05 2017-05-03 Theravance Biopharma R&D IP, LLC Inhibiteurs de la néprilysine
EP3099668B1 (fr) 2014-01-30 2022-05-04 Theravance Biopharma R&D IP, LLC Dérivés de l'acide 5-biphenyl-4-heteroarylcarbonylamino pentanoique comme des inhibiteurs de neprilysin
US9593110B2 (en) 2014-01-30 2017-03-14 Theravence Biopharma R&D IP, LLC Neprilysin inhibitors
WO2016022893A1 (fr) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Composés organiques
KR102345318B1 (ko) 2014-12-02 2021-12-31 현대모비스 주식회사 에이밍 보정 구조를 구비한 차량용 램프
AU2016219362B2 (en) 2015-02-11 2019-11-14 Theravance Biopharma R&D Ip, Llc (2S,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
CA2975269C (fr) 2015-02-19 2023-09-19 Theravance Biopharma R&D Ip, Llc Acide (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]-pentanoique
CN105017154B (zh) * 2015-07-07 2017-10-10 浙江博聚新材料有限公司 一种3‑溴‑1,3,4,5‑四氢‑2h‑1‑苯并氮杂卓‑2‑酮制备方法
HUE055546T2 (hu) 2016-03-08 2021-12-28 Theravance Biopharma R&D Ip Llc Kristályos (2S,4R)-5-(5'-klór-2-fluor-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxi izoxazol-5-karboxamido)-2-metilpentánsav és alkalmazásaik
WO2017172795A1 (fr) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
EP3746081A4 (fr) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. Nouvelles utilisations
PL424453A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
US20230118503A1 (en) * 2020-07-19 2023-04-20 Christopher Turski NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608283A (ja) * 1983-06-29 1985-01-17 Mitsui Toatsu Chem Inc ベンゾチアゼピン誘導体およびその製造方法
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
AU657793B2 (en) * 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
IT1266570B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari
IT1266571B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
SK35496A3 (en) 1997-02-05
PL313433A1 (en) 1996-09-30
ZA961243B (en) 1996-08-27
CA2172354C (fr) 2002-10-08
EP0733642B1 (fr) 2000-11-29
NO961181L (no) 1996-09-24
CN1147506A (zh) 1997-04-16
JPH08269011A (ja) 1996-10-15
PT733642E (pt) 2001-03-30
KR960034178A (ko) 1996-10-22
ES2152444T3 (es) 2001-02-01
EP0733642A1 (fr) 1996-09-25
CZ289245B6 (cs) 2001-12-12
NZ286224A (en) 1997-09-22
KR100482499B1 (ko) 2006-08-23
GR3035410T3 (en) 2001-05-31
IL117265A (en) 2000-07-16
AU4821096A (en) 1996-10-03
HU9600680D0 (en) 1996-05-28
ATE197801T1 (de) 2000-12-15
NO961181D0 (no) 1996-03-22
CZ86396A3 (en) 1996-10-16
CA2172354A1 (fr) 1996-09-24
JP3942670B2 (ja) 2007-07-11
RU2159768C2 (ru) 2000-11-27
HUP9600680A2 (en) 1997-01-28
UA44712C2 (uk) 2002-03-15
DE59606160D1 (de) 2001-01-04
AU701271B2 (en) 1999-01-21
NO305904B1 (no) 1999-08-16
SK281079B6 (sk) 2000-11-07
AR023289A1 (es) 2002-09-04
HUP9600680A3 (en) 1998-07-28
CN1059436C (zh) 2000-12-13
US5677297A (en) 1997-10-14
IL117265A0 (en) 1996-06-18
DK0733642T3 (da) 2001-01-15
HU226064B1 (en) 2008-04-28
PL184336B1 (pl) 2002-10-31
DE19510566A1 (de) 1996-09-26

Similar Documents

Publication Publication Date Title
DZ2003A1 (fr) Dérivés de la benzazépine, de la benzoxazépine et de l&#39;acide benzothiazépine-n-acétique ainsi que leurs procédés de preparation et médicaments contenant ces composés.
FR2714907B1 (fr) Nouveaux dérivés de l&#39;Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant.
DE69630145D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DZ2652A1 (fr) Dérivés d&#39;acides benzazepinon-n-acétiques substitués par des acides phosphoniques leurs procédés de fabrication et médicaments contenant ces composés.
DE69604653D1 (de) Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen
FR2719587B1 (fr) Nouveaux dérivés de l&#39;érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) Nouveaux dérivés de l&#39;érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2711993B1 (fr) Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
CA2207835A1 (fr) Nouveaux derives du 3-(piperid-4-yl) 1,2-benzisoxazole et du 3-(piperazin-4-yl) 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
ATE222250T1 (de) Phenoxypropanolamin-derivate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen zusammensetzungen
FR2708608B1 (fr) Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
FR2709754B1 (fr) Composés 2&#39; ou 3&#39;-déoxy- et 2&#39;, 3&#39;-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
FR2703051B1 (fr) Nouvelles pyridothiadiazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
FR2705673B1 (fr) Compositions comportant des dérivés d&#39;acides aminés, leurs procédés de préparation et leurs utilisations.
DE69608680D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
OA09238A (fr) Dérivés d&#39;isoindolinone, leurs procédés de préparation et les médicaments les contenant.
HRP960356B1 (en) Substituted cinnamic acid guanidides, process for their preparation, their use as medicaments or diagnostic agents, as well as medicaments containing them
FR2708609B1 (fr) Dérivés de méthylguanidine, leurs procédés de préparation ainsi que les compositions en contenant.
FR2687678B1 (fr) Nouveaux derives de l&#39;adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2705346B1 (fr) Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
FR2707638B1 (fr) Nouveaux dérivés d&#39;amino-acides, leurs procédés de préparation et leur application thérapeutique.
OA09439A (fr) &#34;Nouveaux dérivés benzoxazolinoniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent&#34;.
NO975680D0 (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform
NO976056L (no) Fremgangsmåte for fremstilling av enantiomerisk ren azetidin-2-karboksylsyre
DE59008921D1 (de) Dibenzo(1,5)dioxocin-5-one-Derivate, ihre Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung.